Loading...
Supernus Q1 2025 Earnings Report
Supernus Pharmaceuticals, Inc. announced its financial results for the first quarter ended March 31, 2025, highlighting double-digit revenue growth from core products and the launch of ONAPGO.
Key Takeaways
Supernus Pharmaceuticals reported a 4% increase in total revenues to $149.8 million for the first quarter of 2025, driven by strong growth in Qelbree® and GOCOVRI® sales. Despite an increase in operating loss, adjusted operating earnings saw a significant rise. The company also successfully launched ONAPGO™.
Total revenues increased 4% to $149.8 million in Q1 2025 compared to the same period in 2024.
Qelbree® net sales surged by 44% to $64.7 million, and GOCOVRI® net sales increased by 16% to $30.7 million.
Operating loss was $(10.3) million, primarily due to higher contingent consideration loss and increased selling and marketing expenses.
Adjusted operating earnings grew by 16% to $25.9 million.
Revenue by Segment
Forward Guidance
Supernus Pharmaceuticals reiterates its full-year 2025 financial guidance, projecting total revenues between $600 million and $630 million, and adjusted operating earnings between $105 million and $130 million.
Positive Outlook
- Projected total revenues of $600 million - $630 million.
- Anticipated adjusted operating earnings of $105 million - $130 million.
- Continued growth expected from core products.
- Inclusion of approximately $65 million - $75 million from Trokendi XR and Oxtellar XR in total revenues.
- Focus on managing R&D and SG&A expenses within the $435 million - $460 million range.
Challenges Ahead
- Projected GAAP operating loss of $(15) million - $10 million.
- Continued generic erosion of Trokendi XR and Oxtellar XR beginning in September 2024.
- Higher contingent consideration loss impacting operating results.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...